Participants
Tumors, tumor, ≤28
ONCOLOGY, TUMOR, MYELODYSPLASTIC SYNDROME, TUMORS
Eligible patients were ≥18 years of age, with human epidermal growth factor receptor 2 (HER2)‐negative, histologically proven, inoperable locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. All patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1, had received first‐line platinum chemotherapy for ≤28 weeks with a complete response (CR), as determined by the investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), or a confirmed partial response (PR) maintained for ≥4 weeks. Sufficient tumor tissue must have been provided for central laboratory determination of LOH status for randomization and exploratory biomarker analyses.Exclusion criteria included prior treatment with a PARPi, anticancer therapy ≤14 days prior to randomization (including chemotherapy, biologic therapy, immunotherapy, investigational agents, anticancer Chinese medicine, or herbal remedies), diagnosis of myelodysplastic syndrome, and patients who received irradiation as part of prior first‐line treatment.